Reference is made to Aker BioMarine ASA's stock exchange announcement on 26
February 2026 regarding the result of the offer under the Employee Share
Purchase Program and the related share capital increase.
The share capital increase pertaining to the Employee Share Purchase Program has
today been registered with the Norwegian Register of Business Enterprises (Nw.:
Foretaksregisteret). The new registered share capital of the company is NOK 526
341 156, divided into 87 723 526 shares, each with a par value of NOK 6.00. Upon
registration with the Norwegian Central Securities Depository (VPS), the new
shares will be listed on the Oslo Stock Exchange.
For further information, please contact
Lars Jacobsen, General Counsel / SVP
Mobile: +47 90 60 53 06
Email: lars.jacobsen@akerbiomarine.com
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.
About Aker BioMarine:
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.